Abdallah Altarshan, MD
Endocrinology, Diabetes & Metabolism · Evergreen Park, ILNPI 1174582811
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,554 of the $131,795 with a category attached, or 80.8%. Novo Nordisk accounts for 63.2% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $46,297 and has fallen 67.4% since, to $15,073 in 2025. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 845 payments — averaging $155.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$83K
- Johnson & Johnson$30K
- Sanofi-aventis U.S. LLC$4K
- Insulet Corporation$1K
- Mannkind Corporation$1K
- Abbott$1K
- plus $11K from 54 others
What the payments were for
- Consulting fees$2,3102%
- Speaking & faculty fees$106,55481%
- Travel & lodging$1,9782%
- Food & beverage$20,57916%
- Education$3730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$37,899
- RYBELSUS$32,965
- INVOKANA$29,892
- Tresiba$5,888
- DISEASE STATE$2,310
- FREESTYLE LIBRE 3$579
- Omnipod$405
- BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM$395
- DEXCOM G6 TRANSMITTER$367
- TOUJEO$232
- XARELTO$220
- Korlym$201
- CeQur Simplicity$152
- TZIELD$128
- AFREZZA$125
- TEPEZZA$125
- Pogo Automatic Blood Glucose Monitoring System$124
- NATPARA (PARATHYROID HORMONE)$122
- SOLIQUA 100/33$113
- FreeStyle Libre$106
How this compares
$131,795 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,047 | $1,428,253 |
| KorlymMifepristone | 17 | $665,609 |
| JardianceEmpagliflozin | 446 | $413,249 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 187 | $197,917 |
| TrulicityDulaglutide | 172 | $196,277 |
| MounjaroTirzepatide | 160 | $193,551 |
| JanuviaSitagliptin Phosphate | 211 | $175,375 |
| Tresiba Flextouch U-200Insulin Degludec | 132 | $117,721 |
| Tresiba Flextouch U-100Insulin Degludec | 213 | $117,435 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 125 | $105,416 |
| FarxigaDapagliflozin Propanediol | 114 | $96,998 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 94 | $83,493 |
| Humalog Kwikpen U-100Insulin Lispro | 243 | $69,667 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 389 | $59,240 |
| TradjentaLinagliptin | 49 | $58,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $83,247 | $1,570,4691,241 claims |
| Corcept TherapeuticsKorlym | $881 | $665,60917 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr | $904 | $501,773522 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,030 | $427,932478 claims |
| MerckJanuvia, Janumet Xr, Janumet | $24 | $238,282278 claims |
| AstraZenecaFarxiga | $877 | $96,998114 claims |
| Johnson & JohnsonInvokana, Xarelto | $30,406 | $40,12049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Evergreen Park
- Ammar BayrakdarEvergreen Park$517K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
- Silvana PannainChicago$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.